

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.1)*

MediWound Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share

(Title of Class of Securities)

M68830104

(CUSIP Number)

December 31, 2015

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the *Securities Exchange Act* of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSONS Lior Rosenberg	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Israel	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 179,067 (*)
	6	SHARED VOTING POWER 1,710,205 (**)
	7	SOLE DISPOSITIVE POWER 179,067 (*)
	8	SHARED DISPOSITIVE POWER 1,710,205(**)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,899,272 (*) (**)	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.63% (*) (**)	
12	TYPE OF REPORTING PERSON (See instructions) IN	

(*) includes 38,000 ordinary shares subject to currently exercisable options.

(**) Based on 21,850,300 ordinary shares issued and outstanding as of December 31, 2015, as reported in the annual report on the Form 20-F.

1	NAME OF REPORTING PERSONS L.R. Research & Development Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Israel	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,710,205 (*)
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,710,205 (*)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,710,205 (*)	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.81% (*)	
12	TYPE OF REPORTING PERSON (See instructions) CO	

(*) Based on 21,850,300 ordinary shares issued and outstanding as of December 31, 2015, as reported in the annual report on the Form 20-F.

Item 1. (a) Name of Issuer:

MediWound Ltd.

(b) Address of Issuer's Principal Executive Offices:

42 Hayarkon Street Yavne 8122745, Israel

Item 2. (a) Name of Person Filing:

Lior Rosenberg

L.R. Research and Development Ltd.

(b) Address of Principal Business Office:

Lior Rosenberg – 42 Hayarkon Street Yavne 8122745, Israel

L.R. Research and Development Ltd. – 13 Harduf St. Omer 8496500, Israel

(c) Citizenship:

Lior Rosenberg – Israel

L.R. Research and Development Ltd. – Israel

(d) Title of Class of Securities:

Ordinary Shares, par value NIS 0.01 per share

(e) CUSIP Number:

M68830104

Item 3. Not Applicable.

Item 4. Ownership:

(a) Amount beneficially owned:

See rows 5-9 of cover page of each reporting person.

The securities reported herein are beneficially owned as follows:

- 179,067 Ordinary Shares, which amount includes 38,000 ordinary shares subject to currently exercisable options (representing 0.82% of the total Ordinary Shares outstanding) are owned directly by Lior Rosenberg.
- 1,710,205 Ordinary Shares (representing 7.81% of the total Ordinary Shares outstanding) are owned directly by L.R. Research and Development Ltd. in trust for the benefit of Lior Rosenberg. Because Mr. Rosenberg is the sole shareholder of L.R. Research and Development Ltd, he may be deemed to share beneficial ownership in the Ordinary Shares directly beneficially owned by L.R. Research and Development Ltd. Mr. Rosenberg disclaims beneficial ownership in the Ordinary Shares reported on this Schedule 13G except to the extent of his pecuniary interest therein.

(b) Percent of class:

See row 11 of cover page of each reporting person

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

See row 5 of cover page of each reporting person

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page of each reporting person and note in Item 4(a) above

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page of each reporting person

(iv) Shared power to dispose or to direct the disposition of:

See row 8 of cover page of each reporting person and note in Item 4(a) above

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 8, 2016

/s/ Lior Rosenberg

Lior Rosenberg

/s/ L.R. Research and Development Ltd.

By: Lior Rosenberg
Title: Owner and Director

EXHIBIT NO.**DESCRIPTION**

Exhibit 1

Agreement of Joint Filing by and among the Reporting Persons, dated as of February 13, 2015 ⁽¹⁾.

(1) Previously filed with the Securities and Exchange Committee on February 13, 2015 as Exhibit 1 to the reporting persons' schedule 13G and incorporated by reference herein.
